Inovio Biomedical Corporation
11494 Sorrento Valley Road
San Diego,
CA 92121-1318
United States - Map
Phone: 858-597-6006
Fax: 858-597-0451
Web Site: http://www.inovio.com
| Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The companys SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovios proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovios clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, NIH Vaccine Research Center, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005. The company was founded in 1983 and is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Avtar Dhillon M.D., 47
Exec. Chairman |
N/A
| N/A | Mr. Peter D. Kies , 46
Chief Financial Officer |
N/A
| N/A | Mr. Punit S. Dhillon , 28
VP of Fin. and Operations |
N/A
| N/A | Dr. Iacob Mathiesen Ph.D., 42
VP of R&D and Member of Scientific Advisory Board |
N/A
| N/A | Dr. J. Joseph Kim Ph.D., 40
Chief Exec. Officer, Pres |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.00% Nasdaq 
0.01 (0.86%) 
Profile
